Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNF-alpha in glioblastoma

YAEL KUSNE AND EUGENIO ANTONIO CARRERA SILVA (CO-FIRST); ANTHONY S. PERRY; ELISABETH J. RUSHING; EDWARD K. MANDELL; JUSTIN D. DIETRICH; ANDREA E. ERRASTI; DANIEL GIBBS; MICHAEL E. BERENS; JOSEPH C. LOFTUS; CHRISTOPHER HULME; WEIWEI YANG; ZHIMIN LU; KENNETH ALDAPE; NADER SANAI; CARLA V. ROTHLIN; SOURAV GHOSH

SCIENCE SIGNALING

AMER ASSOC ADVANCEMENT SCIENCE

Año: 2014 vol. 7 p. 1 - 15

1937-9145

Grade IV glioblastoma is characterized by increased kinase activity of epidermal growth factor receptor (EGFR); however, EGFR kinase inhibitors have failed to improve survival in individuals with this cancer because resistance to these drugs often develops. Here, we showed that tumor necrosis factor (TNF) produced in the glioblastoma microenvironment activated atypical protein kinase (aPKC), thereby producing resistance to EGFR kinase inhibitors. Additionally, we identified that aPKC was required for both paracrine TNF-dependent activation of the transcription factor NF-B and for tumor cell-intrinsic receptor tyrosine kinase signaling.Targeting aPKC decreased tumor growth in mouse models of glioblastoma, including models of EGFR kinase inhibitor-resistant glioblastoma. Furthermore, aPKC abundance and activity were increased in human glioblastoma tumor cells and high aPKC abundance correlated with poor prognosis. Thus, targeting aPKC might provide an improved molecular approach for glioblastoma therapy